Artiva Biotherapeutics, Inc. ARTV Available-for-sale securities, allowance for credit loss

Available-for-sale securities, allowance for credit loss at other companies

American International GroupAIG

$38M+26.7%

Wells Fargo & CompanyWFC

$5M-85.3%

State StreetSTT

$0—

PNC Financial ServicesPNC

$61M-3.2%

Bar Harbor BanksharesBHB

$636K+117%

Bank of Marin BancorpBMRC

$0—

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s available-for-sale securities, allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s available-for-sale securities, allowance for credit loss?: Artiva Biotherapeutics, Inc. (ARTV) reported available-for-sale securities, allowance for credit loss of $0 in Q1 2026.